Medicare Drug Price Negotiation and HIV: What Is Measured — and What Is Not
Continuity-critical HIV therapy and the boundaries of the CMS negotiation framework
The third cycle of Medicare drug price negotiation includes Biktarvy, an HIV antiretroviral. With its selection, the design question becomes operational: how does the negotiation process evaluate therapies where interruption carries population-level consequences?
CMS collects stakeholder input through an Information Collection Request (ICR). The ICR framework focuses on:
Patient-centered evidence
Treatment value
Unmet needs
Barriers to access and affordability
Adherence challenges
Impact on specific populations and caregivers
This structure evaluates how a therapy functions for individuals and defined patient groups within a clinical and access framework.
The ICR does not include an explicit evaluation of communicable-disease externalities, including resistance emergence or transmission containment risk.
That boundary reflects the statutory design of negotiation, which centers price and therapeutic alternatives. The ICR supports that design.
HIV treatment operates within a dual structure. Antiretroviral therapy (ART) requires uninterrupted use. Treatment interruption is associated with viral rebound, increased transmission risk, and development of multidrug-resistant HIV (MDR-HIV). These consequences extend beyond individual therapeutic substitution. They affect population-level disease containment.
Medicare’s six protected classes policy recognizes that interruption in antiretroviral access carries severe consequences. Negotiation does not remove that designation. However, the ICR does not operationalize communicable-disease continuity as an explicit evaluation criterion.
This creates a structural separation between price methodology and disease-containment governance.
The current data collection asks:
How does the drug function for patients?
It does not ask:
What are the system-level consequences if continuity is destabilized?
Where Biosecurity Enters as System Stability
In this context, national security and biosecurity refer to the stability of communicable-disease containment systems.
Resistance emergence and transmission control are monitored through federal surveillance systems and national HIV strategy coordination mechanisms. These functions are not structurally integrated into CMS negotiation methodology.
A workable next step does not require expanding CMS pricing authority. It requires a consult trigger before final Maximum Fair Price implementation for therapies that:
Are continuity-critical for communicable-disease control
Carry documented resistance risk if interrupted
Such a trigger would require CMS to consult with the relevant federal public health surveillance and national HIV strategy authorities regarding:
Resistance emergence modeling
Transmission containment implications
Alignment with national viral suppression goals
This would not alter CMS’s statutory role. It would align pricing implementation with communicable-disease containment governance already embedded elsewhere in federal policy.
Implementation as Alignment
The question of whether HIV therapies should be subject to negotiation remains a separate policy determination. The structural issue examined here is narrower: if negotiation proceeds, does implementation incorporate communicable-disease continuity as a constraint before final pricing action is set?
Price reform and disease-containment strategy need not operate in conflict. Alignment requires deliberate coupling between pricing authority and public health surveillance functions.
Absent that coupling, continuity protections depend on assumption rather than design. Alignment between pricing authority and disease-containment strategy must be formalized before final pricing determinations are executed.